Proteome Sciences (PRM) AI Stock Analysis

• Market Cap: £5.36M
• Dividend Yield: N/A
• Average Volume (3M): 476.64K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.64
• Revenue Growth: 12.19%
• EPS Growth: 18.12%
• Country: UK
• Employees: 36
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): >-0.01
• Shares Outstanding: 295,182,040
• 10 Day Avg. Volume: 209,671
• 30 Day Avg. Volume: 476,642
• PEG Ratio: -0.08
• Price to Book (P/B): -1.54
• Price to Sales (P/S): 2.05
• P/FCF Ratio: -9.56
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 41 Neutral
• Price Target: 2.00p ▲(9.89% Upside)

The overall stock score is primarily influenced by the company's poor financial performance, with significant risks highlighted by negative equity and cash flow issues. Technical analysis indicates a bearish trend, and valuation metrics are unattractive due to negative earnings. These factors collectively suggest a high-risk investment.

Proteome Sciences Business Overview & Revenue Model

Company Description

Proteome Sciences (PRM) is a biotechnology company that specializes in the analysis of proteins and their roles in biological processes. The company focuses on proteomics, offering advanced technologies and services for the identification, quantification, and characterization of proteins. Its core products include proprietary assays, software solutions, and analytical services that cater to research institutions, pharmaceutical companies, and biotech firms, facilitating drug discovery and development.

How the Company Makes Money

Proteome Sciences generates revenue primarily through the sale of its proteomic services and products. Key revenue streams include contract research services for pharmaceutical and biotechnology companies, where they provide custom proteomics analysis and biomarker discovery services. Additionally, the company earns income from licensing its proprietary technologies and tools to other firms in the industry. Significant partnerships with academic institutions and collaborations with industry leaders also contribute to its earnings, as they often lead to joint research initiatives and shared funding opportunities.

Proteome Sciences Financial Statement Overview

Summary

Proteome Sciences is facing substantial financial challenges across all financial statements. Declining revenues, negative profitability, and high debt levels indicate significant business risks. The negative equity and cash flow issues further exacerbate the company's financial instability.

Income Statement

The company has experienced declining revenue with a decrease from 5.03 million to 4.89 million over the last year, indicating a negative revenue growth rate. The negative EBIT and net income margins highlight ongoing operational challenges with profitability. These factors indicate financial instability in the income statement.

Balance Sheet

The company has a negative stockholders' equity, indicating that liabilities exceed assets, which is a significant concern. The debt-to-equity ratio cannot be calculated due to negative equity, but the high total debt level suggests potential solvency issues. This balance sheet position suggests high financial risk.

Cash Flow

Operating cash flow is negative, and free cash flow has worsened, indicating cash flow difficulties. The free cash flow to net income ratio is negative, reflecting challenges in generating cash relative to net income. These factors demonstrate weak cash flow management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.53M	4.89M	5.03M	23.74B	22.59B	16.95B
Gross Profit	-32.00K	670.00K	1.65M	4.77M	2.96M	2.58M
EBITDA	-1.45M	-1.51M	-1.14M	2.13M	625.00K	714.00K
Net Income	-3.33M	-3.41M	-2.44M	1.32M	72.00K	295.00K
Balance Sheet
Total Assets	8.35M	9.21M	11.46M	12.43M	10.04M	9.09M
Cash, Cash Equivalents and Short-Term Investments	263.00K	1.13M	2.03M	3.99M	2.39M	2.21M
Total Debt	15.39M	14.52M	13.47M	11.91M	11.69M	11.04M
Total Liabilities	16.93M	15.72M	14.52M	13.28M	12.82M	12.45M
Stockholders Equity	-8.58M	-6.52M	-3.07M	-843.00K	-2.77M	-3.36M
Cash Flow
Free Cash Flow	-1.48M	-1.05M	-718.00K	2.14B	8.80B	-9.07B
Operating Cash Flow	-1.21M	-826.00K	-481.00K	3.88B	10.52B	-7.74B
Investing Cash Flow	-273.00K	-224.00K	-424.00K	-21.67B	4.27B	-18.38B
Financing Cash Flow	368.00K	151.00K	-1.06M	-209.00K	-400.00K	-146.00K

Proteome Sciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.82
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:PRM, the sentiment is Negative. The current price of 1.82 is below the 20-day moving average (MA) of 1.93, below the 50-day MA of 2.53, and below the 200-day MA of 3.29, indicating a bearish trend. The MACD of -0.13 indicates Negative momentum. The RSI at 41.80 is Neutral, neither overbought nor oversold. The STOCH value of 38.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:PRM.

Proteome Sciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ABDX	―	£15.11M	―	―	―	27.60%	1.35%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GDR	―	£10.75M	―	―	―	125.37%	22.47%
IXI	―	£10.43M	-4.83	-13.85%	―	7.27%	39.64%
GENI	―	£10.33M	―	-181.41%	―	12.12%	54.24%
PRM	―	£5.36M	-1.61	―	―	12.19%	18.12%
OBD	―	£6.36M	-0.11	-333.59%	―	45.22%	55.71%

Proteome Sciences Corporate Events

Proteome Sciences Sees Growth in Services Amid Revenue Challenges

Proteome Sciences reported a decline in total revenues for the first half of 2025, attributed to global trade upheavals and cuts in US research funding. Despite these challenges, the company’s proteomics services showed significant growth, particularly in Frankfurt and San Diego, with expectations of continued demand into 2026. The company is optimistic about future revenue growth, driven by increased orders and new product developments like DXT tags for multiplexing. However, sales of TMT reagents have been impacted by reduced R&D funding, though improvements are anticipated as the industry adapts.

The most recent analyst rating on (GB:PRM) stock is a Hold with a £3.00 price target. To see the full list of analyst forecasts on Proteome Sciences stock, see the GB:PRM Stock Forecast page.